# US 2022/0275104 A1 · Gd2 binding molecule

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0275104 A1
- Document ID: US20220275104A1
- Status: Published application
- Kind: A1
- Application number: 17/631,745
- Filed: 2020-07-31
- Published: 2022-09-01
- Earliest claimed: 2019-08-01
- Assignees: Mie University
- Applicants: Mie University
- Inventors: Hiroshi SHIKU; Yasushi AKAHORI; Hiroshi MIWA; Hiroshi FUJIWARA; Koichi FURUKAWA; Keiko FURUKAWA; Yuhsuke OHMI
- Web page: https://patentgrep.com/patent/US20220275104A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 16/3084: {against tumour-associated gangliosides}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4258: {Gangliosides, e.g. GM2, GD2 or GD3}
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 5/067: {Hepatocytes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/505: {comprising antibodies}
- A61K 2239/46: characterised by the cancer treated
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2510/00: Genetically modified cells
- C12N 2740/10043: viral genome or elements thereof as genetic vector
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided is a cancer treatment or prevention technique that molecularly targets GD2. A GD2-binding molecule includes a heavy-chain variable region containing a heavy-chain CDR1 containing the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 containing the amino acid sequence represented by SEQ ID NO: 2, and a heavy-chain CDR3 containing the amino acid sequence represented by SEQ ID NO: 3, and/or a light-chain variable region containing a light-chain CDR1 containing the amino acid sequence represented by SEQ ID NO: 9, a light-chain CDR2 containing the amino acid sequence represented by SEQ ID NO: 10, and a light-chain CDR3 containing the amino acid sequence represented by SEQ ID NO: 11.

## Claims

### Claim 1

A chimeric antigen receptor comprising a GD2-binding domain comprising
a heavy-chain variable region containing
a heavy-chain CDR1 containing the amino acid sequence represented by SEQ ID NO: 1,
a heavy-chain CDR2 containing the amino acid sequence represented by SEQ ID NO: 2, and
a heavy-chain CDR3 containing the amino acid sequence represented by SEQ ID NO: 3, and
a light-chain variable region containing
a light-chain CDR1 containing the amino acid sequence represented by SEQ ID NO: 9,
a light-chain CDR2 containing the amino acid sequence represented by SEQ ID NO: 10, and
a light-chain CDR3 containing the amino acid sequence represented by SEQ ID NO: 11.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the binding capability of the chimeric antigen receptor to ganglioside GD1a, ganglioside GD1b, ganglioside GD3, ganglioside GM1, ganglioside GM3, ganglioside GT1b, or lactosylceramide is equal to or less than ½ of the binding capability of the chimeric antigen receptor to ganglioside GD2.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The chimeric antigen receptor according to claim 1, comprising a core domain containing
a scFv domain that contains the heavy-chain variable region and the light-chain variable region,
a transmembrane domain, and
an intracellular domain of TCR.

### Claim 6 (depends on 5)

The chimeric antigen receptor according to claim 5, wherein the core domain further contains an intracellular domain of a co-stimulator.

### Claim 7 (depends on 5)

The chimeric antigen receptor according to claim 5, comprising a GITRL domain at a position closer to the C-terminus of the core domain via a self-cleaving peptide domain.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

A polynucleotide encoding the chimeric antigen receptor of claim 1.

### Claim 10 (depends on 9)

An isolated cell comprising the polynucleotide of claim 9.

### Claim 11 (depends on 9)

A chimeric antigen receptor T-cell or chimeric antigen receptor NK-cell comprising the polynucleotide of claim 9.

### Claim 12 (depends on 11)

A pharmaceutical composition comprising the chimeric antigen receptor T-cell or the chimeric antigen receptor NK-cell of claim 11.

### Claim 13 (depends on 12)

A method of treating or preventing cancer, the method comprising administering the pharmaceutical composition according to claim 12 to a subject in need thereof.

### Claim 14 (depends on 3)

The chimeric antigen receptor according to claim 3, comprising a core domain containing
a scFv domain that contains the heavy-chain variable region and the light-chain variable region,
a transmembrane domain, and
an intracellular domain of TCR.

### Claim 15 (depends on 14)

The chimeric antigen receptor according to claim 14, wherein the core domain further contains an intracellular domain of a co-stimulator.

### Claim 16 (depends on 15)

The chimeric antigen receptor according to claim 15, comprising a GITRL domain at a position closer to the C-terminus of the core domain via a self-cleaving peptide domain.

### Claim 17 (depends on 16)

A polynucleotide encoding the chimeric antigen receptor of claim 16.

### Claim 18 (depends on 17)

A cell comprising the polynucleotide of claim 17.

### Claim 19 (depends on 17)

A chimeric antigen receptor T-cell or chimeric antigen receptor NK-cell comprising the polynucleotide of claim 17.

### Claim 20 (depends on 19)

A pharmaceutical composition comprising the chimeric antigen receptor T-cell or the chimeric antigen receptor NK-cell of claim 19.

### Claim 21 (depends on 20)

The pharmaceutical composition according to claim 20, which is for use in the treatment or prevention of cancer.
